Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:FBIO

Fortress Biotech Q3 2026 Earnings Date & Estimates

Fortress Biotech logo
$1.87 0.00 (0.00%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$1.93 +0.06 (+3.21%)
As of 10/16/2026 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fortress Biotech is estimated to report Q3 2026 earnings on Monday, November 16, 2026, before market opens. The conference call is scheduled for November 11, 2026 at 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Fortress Biotech in Q3 2026

Fortress Biotech is expected to post earnings of -$0.27 per share on revenue of $21.58 million. In the same quarter a year earlier Fortress Biotech reported $0.11 per share on revenue of $17.63 million. Fortress Biotech last reported on August 13, 2026, posting -$0.08 per share and beating the -$0.20 consensus estimate. Fortress Biotech has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.27
Expected Revenue
$21.58 million
Prior-Year EPS
$0.11
Prior-Year Revenue
$17.63 million
Expected EPS Growth
-345.5%
Expected Revenue Growth
+22.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.08 (Beat by +$0.12)
Last Quarter Revenue
$18.72 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Fortress Biotech Q3 2026 Earnings FAQ

Fortress Biotech (NASDAQ:FBIO) is estimated to report Q3 2026 earnings on Monday, November 16, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Fortress Biotech's Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Fortress Biotech to post earnings of -$0.27 per share for Q3 2026.

The consensus revenue estimate for Fortress Biotech is $21.58 million for Q3 2026.

Fortress Biotech Earnings Headlines

Comparing 60 Degrees Pharmaceuticals (NASDAQ:SXTP) & Fortress Biotech (NASDAQ:FBIO)
October 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31108259
Reviewing Johnson & Johnson (NYSE:JNJ) and Fortress Biotech (NASDAQ:FBIO)
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31105017
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.tc pixel
 |  Altimetry (Ad)
Head-To-Head Survey: 60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Fortress Biotech (NASDAQ:FBIO)
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104717
Journey Medical Corporation to Participate in September 2026 Investor Conferences
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3358111/0/en/journey-medical-corporation-to-participate-in-september-2026-investor-conferences.html
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357555/28889/en/fortress-biotech-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference.html
See More Fortress Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fortress Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fortress Biotech and other key companies, straight to your email.

About Fortress Biotech

Fortress Biotech (NASDAQ:FBIO) is a biopharmaceutical company that develops and commercializes prescription medicines for serious and underserved medical conditions. Its research and development activities span areas including dermatology, oncology, autoimmune diseases, rare diseases, and other specialty indications.

The company operates through a network of subsidiary companies and strategic partnerships, using a platform designed to advance drug candidates from development through regulatory approval and commercialization. Its portfolio has included prescription therapies and investigational programs, with products and candidates addressing conditions that may require specialized treatment or have limited therapeutic options.

Fortress Biotech is headquartered in Miami, Florida, and primarily serves the U.S. pharmaceutical market through its operating companies and commercial partners. The company was founded in 2014 and is led by Lindsay A. Rosenwald, M.D., who serves as its founder, chairman, and chief executive officer.

View Fortress Biotech Profile
Earnings Tools